SCHEMBL25801711

SCHEMBL25801711

CCCCCCCCc1ccc(CCl)nn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.52
CYP19A1 P11511 9/20 0.44
THRA P10827 1/20 0.39
THRB P10828 1/20 0.39
ESR1 P03372 2/20 0.38
ADRA2A P08913 2/20 0.38
ADORA3 P0DMS8 2/20 0.38
TACR2 P21452 2/20 0.38
SLC6A2 P23975 2/20 0.38
SLC6A4 P31645 2/20 0.38
SLC6A3 Q01959 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
SHBG P04278 1/20 0.38
TP53 P04637 1/20 0.38
CYP3A4 P08684 1/20 0.38
HSPD1 P10809 1/20 0.38
ADRB3 P13945 1/20 0.38
HTR2C P28335 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27602446 0.92 KCNH2 (0.41) KCNH2CYP19A1ESR1SLC5A2MIF
SCHEMBL22941955 0.89 KCNH2 (0.61) KCNH2CYP19A1ESR1ADRA2AADORA3
SCHEMBL12356537 0.87 KCNH2 (0.59) KCNH2CYP19A1ESR1ADRA2AADORA3
SCHEMBL8551658 0.82 KCNH2 (0.50) KCNH2CYP19A1ESR1ADRA2AADORA3
SCHEMBL9850641 0.82 KCNH2 (0.50) KCNH2CYP19A1ESR1ADRA2AADORA3
SCHEMBL941277 0.80 KCNH2 (0.47) KCNH2CYP19A1ESR1ADRA2AADORA3
SCHEMBL14722461 0.78 KCNH2 (0.48) KCNH2CYP19A1ESR1ADRA2AADORA3
SCHEMBL12668129 0.77 KCNH2 (0.48) KCNH2CYP19A1ESR1ADRA2AADORA3
SCHEMBL9552547 0.77 KDM4E (0.44) KCNH2CYP19A1THRATHRBESR1
SCHEMBL12356544 0.76 KCNH2 (0.45) KCNH2CYP19A1ESR1ADRA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081511-B3 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LTD (GB) 2026-03-04 EP disclosed
EP-4442319-A2 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2024-10-09 EP disclosed
EP-4081511-B1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LTD (GB) 2024-07-31 EP disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 US disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 KCNH2 4192/4885CYP19A1 3786/4885THRA 3922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.